Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib continuation protocol in ALK-positive or ROS1-positive NSCLC
2021-005569-42Phase 4Active
- Sponsor
- Pfizer
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lorlatinib in ALK-positive non-small cell lung cancer and non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Dec 2021; status: active.
02
Drugs
lorlatinib
03
Conditions
ALK-positive non-small cell lung cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-005569-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005569-42.